Immatics N.V. (IMTX)
Automate Your Wheel Strategy on IMTX
With Tiblio's Option Bot, you can configure your own wheel strategy including IMTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMTX
- Rev/Share 1.4754
- Book/Share 5.4361
- PB 0.9255
- Debt/Equity 0.0282
- CurrentRatio 9.2599
- ROIC -0.0437
- MktCap 611548437.5
- FreeCF/Share -1.6526
- PFCF -3.4994
- PE 35.0042
- Debt/Assets 0.0233
- DivYield 0
- ROE 0.0348
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IMTX | Deutsche Bank | -- | Buy | -- | $10 | May 28, 2025 |
| Initiation | IMTX | Piper Sandler | -- | Overweight | -- | $19 | Oct. 7, 2024 |
News
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois.
Read More
Immatics N.V.: Trading Below Cash, But Not Without Reason
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Negative
Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but negative enterprise value due to early-stage data and long catalyst desert. Phase 3 trial for IMA203 will produce interim data in early 2026, with no clear topline data timeline, creating uncertainty.
Read More
Immatics Announces Full Year 2024 Financial Results and Business Update
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.
Read More
New Strong Buy Stocks for February 12th
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
BOH, AUB, BHRB, IMTX and RH have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2025.
Read More
About Immatics N.V. (IMTX)
- IPO Date 2018-12-12
- Website https://www.immatics.com
- Industry Biotechnology
- CEO Dr. Harpreet Singh Ph.D.
- Employees 554